Hepatic steatosis in hepatitis B virus infected patients: Meta-analysis of risk factors and comparison with hepatitis C infected patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 9, 2011, Pages 1361-1367

  Machado, Mariana V ^a   Oliveira, António G ^b   Cortez Pinto, Helena ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b Anatomy Department   (Portugal)

Author keywords

Fatty liver; Hepatitis B; Hepatitis C; Prevalence; Steatosis

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; HEPATITIS B(E) ANTIGEN; TRIACYLGLYCEROL; VIRUS DNA;

ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FATTY LIVER; FIBROSIS; GENOTYPE; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; META ANALYSIS; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80052386721     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06801.x     Document Type: Article

References (44)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004; 11: 97-107.
2. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
3. Leandro G, Mangia A, Hui J etal. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
4. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-6.
5. Soresi M, Tripi S, Franco V etal. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int. 2006; 26: 1119-25.
6. Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int. J. Obes. (Lond) 2007; 31: 871-5.
7. Jan CF, Chen CJ, Chiu YH etal. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int. J. Obes. (Lond) 2006; 30: 794-9.
8. Wong GL, Wong VW, Choi PC etal. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111-17.
9. Kim KH, Shin HJ, Kim K etal. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 2007; 132: 1955-67.
10. Kim K, Kim KH, Kim HH, Cheong J. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem. J. 2008; 416: 219-30.
11. Na TY, Shin YK, Roh KJ etal. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009; 49: 1122-31.
12. Kim JY, Song EH, Lee HJ etal. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J. Mol. Biol. 2010; 397: 917-31.
13. Stroup DF, Berlin JA, Morton SC etal. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials. 1986; 7: 177-88.
15. Lefkowitch JH, Schiff ER, Davis GL etal. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993; 104: 595-603.
16. Malhotra V, Sakhuja P, Gondal R, Sarin SK, Siddhu M, Dutt N. Histological comparison of chronic hepatitis B and C in an Indian population. Trop. Gastroenterol. 2000; 21: 20-1.
17. Rozario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J. Hepatol. 2003; 38: 223-9.
18. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J. Hepatol. 2005; 43: 38-44.
19. Altiparmak E, Koklu S, Yalinkilic M etal. Viral and host causes of fatty liver in chronic hepatitis B. World J. Gastroenterol. 2005; 11: 3056-9.
20. Thomopoulos KC, Arvaniti V, Tsamantas AC etal. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur. J. Gastroenterol. Hepatol. 2006; 18: 233-7.
21. Papatheodoridis GV, Chrysanthos N, Savvas S etal. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J. Viral Hepat. 2006; 13: 303-10.
22. Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J. Clin. Gastroenterol. 2007; 41: 513-17.
23. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Archimandritis AJ. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig. Liver Dis. 2007; 39: 936-42.
24. Peng D, Han Y, Ding H, Wei L. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J. Gastroenterol. Hepatol. 2008; 23: 1082-8.
25. Shi JP, Fan JG, Wu R etal. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J. Gastroenterol. Hepatol. 2008; 23: 1419-25.
26. Minakari M, Molaei M, Shalmani HM etal. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur. J. Gastroenterol. Hepatol. 2009; 21: 512-16.
27. Yun JW, Cho YK, Park JH etal. Hepatic steatosis and fibrosis in young men with treatment-naive chronic hepatitis B. Liver Int. 2009; 29: 878-83.
28. Tsochatzis E, Papatheodoridis GV, Manolakopoulos S, Tiniakos DG, Manesis EK, Archimandritis AJ. Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand. J. Gastroenterol. 2009; 44: 752-9.
29. Wong VW, Wong GL, Yu J etal. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am. J. Gastroenterol. 2010; 105: 132-8.
30. Vere CC, Neagoe D, Streba CT etal. Steatosis and serum lipid patterns in patients with chronic viral hepatitis: differences related to viral etiology. Rom. J. Morphol. Embryol. 2010; 51: 509-14.
31. Zheng RD, Xu CR, Jiang L, Dou AX, Zhou K, Lu LG. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int. J. Med. Sci. 2010; 7: 272-7.
32. Demir K, Akyuz F, Ozdil S etal. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? Ann. Hepatol. 2007; 6: 92-6.
33. Giannattasio A, Cirillo F, Terlizzi V, Liccardo D, Vecchione R, Iorio R. Hepatic steatosis is uncommon in children with chronic hepatitis B. J. Clin. Virol. 2009; 46: 360-2.
34. Persico M, Masarone M, La Mura V etal. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J. Gastroenterol. 2009; 15: 462-6.
35. Bondini S, Kallman J, Wheeler A etal. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int. 2007; 27: 607-11.
36. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-74.
37. Ishak K, Baptista A, Bianchi L etal. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696-9.
38. Ratziu V, Charlotte F, Heurtier A etal. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
39. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010; 53: 372-84.
40. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 2010; 28: 155-61.
41. Weston SR, Leyden W, Murphy R etal. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-9.
42. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol. 2003; 98: 2042-7.
43. Marchesini G, Brizi M, Bianchi G etal. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
44. Machado MV, Cortez-Pinto H. Insulin resistance and steatosis in chronic hepatitis C. Ann. Hepatol. 2009; 8 (Suppl. 1): S67-75.